Tranzyme Stomach Paralysis Drug Comes Up Short

by Web Master, Benzinga Editor

November 15, 2012 8:45 AM | 4 seconds read | Make a Comment

A mid-stage study of Tranzyme's TZP-102 failed to improve stomach mobility in diabetics.

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.